{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-25-105733","form_type":"8-K/A","ticker":"ABPO","cik":"0001893219","company_name":"Abpro Holdings, Inc.","filed_at":"2025-11-04T23:59:59+00:00","discovered_at":"2026-05-14T18:02:41.001624+00:00","generated_at":"2026-05-17T00:43:30.620884+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Abpro/Celltrion present preclinical data for CT-P72/ABP-102 at SITC 2025; poster in top 150","bullets":["Poster selected as one of Top 150 abstracts out of >1,300 submissions at SITC 2025.","CT-P72/ABP-102 demonstrated potent anti-tumor activity in HER2-high models, including Enhertu-resistant tumors.","Dual-affinity engineering reduced on-target/off-tumor activity; favorable safety in non-human primates.","Data supports advancement toward IND and first-in-human trial planned for next year.","Built on Abpro's DiversImmune® platform for rapid engineering of next-generation antibodies."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-25-105733","json":"https://secwatch.observer/filing/0001213900-25-105733.json","markdown":"https://secwatch.observer/filing/0001213900-25-105733.md","text":"https://secwatch.observer/filing/0001213900-25-105733.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1893219/000121390025105733/0001213900-25-105733-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1893219/000121390025105733/ea0263868-8ka1_abpro.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T00:43:30.620884+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}